Eur Rev Med Pharmacol Sci 2022; 26 (14): 4991-4996

DOI: 10.26355/eurrev_202207_29285

The relationship between complete hydatidiform mole and serum Vitamin D level: a prospective case-control study

R. Gündüz, U. Değer, I. Kaplan, N. Bayramoğlu Tepe, S. Yaman Tunç, M.S. Içen, E. Ağaçayak, M.S. Evsen

Department of Obstetrics and Gynecology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey. ryhn.gunduz@gmail.com


OBJECTIVE: This study aimed to determine whether or not there was a relationship between complete hydatidiform mole (CHM) and serum Vitamin D level by comparing CHM patients with two control groups and to determine whether or not Vitamin D deficiency is a risk factor for CHM.

PATIENTS AND METHODS: This prospective study included 30 patients diagnosed with CHM (case group), 30 patients in the first trimester of a healthy pregnancy (control group), and 30 healthy non-pregnant subjects (control group). A record was made of serum 25-hydroxyvitamin D (25-OH D vitamin) levels, age, body mass index (BMI), gravida, parity, and the number of abortus. The serum 25-OH D vitamin levels were examined in each group and compared between groups.

RESULTS: The 25-OH D vitamin level of all the patients in the study was determined as 11.16±8.64 ng/mL. No significant difference was determined between the groups in respect of 25 OH-D vitamin levels. When comparisons were made between the four subgroups according to the 25-OH-D level, no significant difference was determined between the CHM and control groups. When the patients were separated as obese and non-obese groups, no significant difference was determined between the groups.

CONCLUSIONS: Severe deficiency, deficiency, or insufficient levels of serum Vitamin D are not thought to be risk factors for CHM patients.

Free PDF Download

To cite this article

R. Gündüz, U. Değer, I. Kaplan, N. Bayramoğlu Tepe, S. Yaman Tunç, M.S. Içen, E. Ağaçayak, M.S. Evsen
The relationship between complete hydatidiform mole and serum Vitamin D level: a prospective case-control study

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 14
Pages: 4991-4996
DOI: 10.26355/eurrev_202207_29285